Duration and method of taking giritinib to treat AML

Giritinib, as a highly effective protein kinase inhibitor targeting acute myeloid leukemia (AML) caused by FLT3 gene mutations, has been widely recognized in clinical practice. However, many patients still have concerns about the duration and method of taking it. This article will provide detailed answers to these two core questions to help patients better use this drug.

First of all, regarding the treatment duration of giritinib, this is not an immutable standard, but needs to be comprehensively determined based on the patient's specific condition, treatment response, and the doctor's personalized advice. The treatment of AML often requires multiple methods. Giritinib is usually used as part of comprehensive treatment and works in conjunction with other treatments. Therefore, patients should develop an appropriate treatment duration under the guidance of a doctor, combined with their own treatment plan and body response. It should be noted that the therapeutic response of giritinib may be slow, so in the absence of disease progression or intolerable toxicity, patients need to adhere to treatment for at least 6 months so that the drug can fully exert its efficacy.

When taking giritinib, patients should strictly follow their doctor's instructions. The starting dose of giritinib is usually 120 mg once daily, but this dose may be adjusted appropriately based on patient response. During the period of taking the medicine, you should receive regular blood and physical examinations so that the doctor can understand the treatment effect in time and adjust the drug dosage or treatment plan as needed.

In addition, taking giritinib may also be accompanied by some side effects, such as nausea, vomiting, diarrhea, etc. If the patient experiences any discomfort or abnormal reaction during taking, the patient should inform the doctor immediately so that timely treatment and medication adjustment can be obtained. In addition, simultaneous use with other drugs should be avoided to avoid drug interactions and affect the efficacy of giritinib.

It should be noted that although giritinib has been approved for marketing in China, its high price still prohibits many patients. Fortunately, there are some more affordable generic drug options available in overseas markets. However, when choosing these drugs, patients still need to be cautious to ensure the formality and safety of the drug sources and avoid affecting the treatment effect due to drug quality issues.